Recently, amplification of the RTK gene MET has been shown to bypass EGFR receptor inhibition in human lung cancer cells and was present in 4 of 18 lung cancer specimens that developed resistance to gefitinib or erlotinib, supporting the idea that MET should also be targeted in EGFR-dependent cancers [160]. This evidence concerns the gene MET and cancer.